People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. | — | Biotechnology | Series C | $178.6M | $433.3M | 2015 |
| Soleno Therapeutics Inc | — | Pharma | Series C | $98.6M | $680.6M | 2012 |
| Celladon Corp | — | Biotechnology | Series B | $70.9M | $119.1M | 2016 |
| Semnur Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2013 |
| Synapse Biomedical Inc | — | Biotechnology | Pre-Seed | $1.2M | $9.7M | 2009 |
Edgar G Engleman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edgar G Engleman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mahendra G. Shah | 2 | 3 |
| Asish Xavier | 1 | 18 |
| William Harris | 1 | 9 |
| Ernest Mario | 1 | 9 |
| James Healy | 1 | 8 |
| Richard Miller | 1 | 8 |
| Peter Moldt | 1 | 6 |
| Rajen Dalal | 1 | 5 |
| Andrew Sinclair | 1 | 5 |
| Mahendra Shah | 1 | 5 |
| Matthew Pauls | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| Andrew E. Senyei | 1 | 3 |
| James H. Welch | 1 | 3 |
| Krisztina Zsebo | 1 | 3 |
| Ashish Khanna | 1 | 3 |
| Steinar Engelsen | 1 | 2 |
| Thomas J. Dietz | 1 | 2 |
| William G. Harris | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.